Parenteral in Medical Technology

NPS Reports Successful GATTEX(TM) Extension Study

... for short bowel syndrome (SBS) patients who are dependent upon parenteral nutrition (PN). The extension study enrolled 65 of the 71 patients (91%) ... effective potential therapy for short bowel syndrome patients dependent on parenteral Nutrition. This study provides interesting and very promising results, as ...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

... the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa , including drug resistant isolates. ...

Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever

... the last injectable drug for the reduction of fever in the United States, but since it was taken off the market in 1976, there has been no approved parenteral antipyretic drug available. About Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals is a biopharmaceutical company focused on ...

BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results

... peramivir as a treatment option for an influenza emergency," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "With its parenteral route of administration, peramivir has the potential to help patients who may have difficulty with an oral or inhaled anti-viral medication. In ...

Schering-Plough Announces Results of the Early ACS Trial

... within the preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; dependency on renal dialysis; or known hypersensitivity to any component of the product. In patients undergoing PCI, ...

DaVita Abstracts Highlight Latest Research Developments at Annual Dialysis Conference

... Technique with Keloid-Scarred Skin Sylvia Donato-Moore, BSN, RN, CNN -- Experience with Intradialytic parenteral Nutrition at a Pediatric Hemodialysis Unit Kathleen Traficanti, BS, RD -- NxStage(R) Pureflow SL Culture and LAL ...

Interleukin Genetics Wins International Award for Outstanding Research Published in the Journal, Nutrition

... Inc. (Amex: ILI ), today received the 12th John M. Kinney Award for Nutrition and Metabolism at the annual Congress of the European Society of parenteral and Enteral Nutrition, in Florence, Italy. The award was given for the paper, "Interleukin-1 genotype-selective inhibition of inflammatory mediators ...

Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent

... years of age or weighing less than 15 kg (33 lbs). Myocardial infarction and cerebrovascular spasm and occlusion have been reported following parenteral use of phentolamine, usually in association with marked hypotensive episodes producing shock-like states. Tachycardia, bradycardia, and cardiac ...

Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection

... as sodium sulfide, in a number of disease models. Preclinical data demonstrate the therapeutic potential of IK-1001 (sodium sulfide) for injection, a parenteral injectable formulation of hydrogen sulfide, in a variety of disease models including myocardial infarction, cardiopulmonary bypass surgery, ...

Genta Receives Key Patent Related to Oral Gallium Compound G4544

... Company to Seek Buyer for Marketed parenteral Product Ganite(R) BERKELEY HEIGHTS, N.J., April 14 /PRNewswire/ -- Genta Incorporated (Nasdaq: GNTA ) today announced that the Company has ...

AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma

... as a single agent to treat malignant melanoma, median overall survival has ranged from 6-8 months. About Amplimexon Amplimexon is AmpliMed's parenteral formulation of imexon. Imexon is a cyanoaziridine compound which showed tantalizing evidence of activity in limited studies in lung cancer, melanoma ...

Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting

... within the preceding six weeks; history of stroke within 30 days, or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb-IIIa inhibitor; dependency on renal dialysis; or known hypersensitivity to any component of the product. Bleeding is the most common ...

Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study

... Sixteen of the 35 patients (45.7%) receiving the low dose of GATTEX (0.05 milligrams/kilogram/day) demonstrated a 20 percent or greater reduction in parenteral nutrition (PN) (p-value 0.007), compared to eight of 32 patients (25%) in the high-dose group (0.10 mg/kg/day) (p-value 0.161), and one of 16 ...

Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer

... bullous skin eruptions, and anaphylaxis. Respiratory: Very common: Dyspnoea. Bronchospasm occurs uncommonly and is usually mild and transient, but parenteral therapy may be required. In the rare event of pulmonary oedema, interstitial pneumonitis, or adult respiratory distress syndrome (ARDS) gemcitabine ...

Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)

... MDS and AML. In addition, the trial will examine pharmacokinetics and pharmacodynamic effects of orally administered Azacitidine, as compared with parenteral Vidaza. Pharmion will hold a conference call to discuss these results later this morning, August 2, at 9:00 a.m. ET. The conference call will ...

BDSI Announces Positive Phase III Clinical Trial Results for BEMA Fentanyl

... of BEMA(TM) Fentanyl augers very well for the potential application of the BEMA(TM) technology to other therapeutics that normally require parenteral administration. While it is true that work remains to be completed in the regulatory and commercial areas for BEMA(TM) Fentanyl, now that we ...

Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting

... and alcoholism. Chronic abuse can lead to marked tolerance and psychological dependence. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic ...

12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)

... and alcoholism. Chronic abuse can lead to marked tolerance and psychological dependence. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic ...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

... said Patrick J. Mahaffy, president and CEO of Pharmion. "These studies will help provide us with insight not only into the continuing development of parenteral Vidaza, but, in particular, provide us direction for the development of oral azacitidine." Tolerability and hematologic improvement assessed using ...

Positive Aggrastat Results Featured in the Journal of the American College of Cardiology

... hypertension (systolic blood pressure greater than 180 mmHg and/or diastolic blood pressure greater than 110 mmHg); concomitant use of another parenteral GP IIb/IIIa inhibitor; or acute pericarditis. Bleeding is the most common complication encountered during therapy with AGGRASTATR. Administration ...